Evicenter
Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Datroway (opens in a new tab)
Questions
42
Last updated

All questions

Clinical trials: Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer

5 questions · 4 sources

Clinical trials

How was the DATROWAY TROPION-Breast01 trial designed?

Study results

How long does DATROWAY delay breast cancer progression compared with chemotherapy (TROPION-Breast01)?

Do patients live longer on DATROWAY than on chemotherapy (TROPION-Breast01)?

What was the DATROWAY response rate in TROPION-Breast01?

What percentage of DATROWAY patients had no progression at 9 and 12 months (TROPION-Breast01)?